Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

A mouse model for studying therapy-induced cancers.

Anna T Meadows1

  • 1The Children's Hospital of Philadelphia, University of Pennsylvania School of Medicine, Philadelphia, PA 19104, USA. meadows@email.chop.edu

Cancer Cell
|October 18, 2005
PubMed
Summary

Pediatric cancer survivors face increased risks of secondary malignant neoplasms (SMNs). A new study shows Nf1-mutated mice treated with chemotherapy or radiation developed SMNs more frequently, offering a model to study and reduce these risks.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Risk of solid subsequent malignant neoplasms after childhood Hodgkin lymphoma-Identification of high-risk populations to guide surveillance: A report from the Late Effects Study Group.

Cancer·2018
Same author

Systemic neoadjuvant chemotherapy for Group B intraocular retinoblastoma (ARET0331): A report from the Children's Oncology Group.

Pediatric blood & cancer·2016
Same author

The ASPHO 2014 distinguished career award goes to Dr. Beverly Lange.

Pediatric blood & cancer·2014
Same author

Reply: To PMID 23876864.

American journal of ophthalmology·2013
Same author

Incidence of pineal gland cyst and pineoblastoma in children with retinoblastoma during the chemoreduction era.

American journal of ophthalmology·2013
Same author

Relevance of historical therapeutic approaches to the contemporary treatment of pediatric solid tumors.

Pediatric blood & cancer·2013

Area of Science:

  • Oncology
  • Genetics
  • Cancer Research

Background:

  • Long-term survival in pediatric cancer patients is increasing.
  • Therapy-induced second malignant neoplasms (SMNs) are a growing concern for these survivors.
  • Understanding the mechanisms behind SMNs is crucial for improving patient outcomes.

Purpose of the Study:

  • To investigate the potential of a mouse model with a mutation in the Nf1 gene for studying therapy-induced second malignant neoplasms (SMNs).
  • To evaluate the rate of SMN development in Nf1-mutated mice compared to wild-type controls when exposed to genotoxic agents.

Main Methods:

  • Mice with a mutation in the Nf1 gene (neurofibromatosis type 1) were treated with radiation and/or cyclophosphamide.
  • Tumor development rates in Nf1-mutated mice were compared to similarly treated wild-type control mice.

Related Experiment Videos

  • Tumor types observed in the study were analyzed for similarity to human SMNs.

    • Main Results:

    • Nf1-mutated mice developed tumors similar to human SMNs at a significantly higher rate than wild-type controls.
    • The study demonstrated a clear link between Nf1 mutation, genotoxic treatment, and increased SMN incidence.
    • The developed mouse model efficiently recapitulates key aspects of therapy-induced SMN development.

    Conclusions:

    • The Nf1-mutated mouse model is a valuable tool for studying the mechanisms of therapy-induced SMNs.
    • This model can be used to test interventions aimed at reducing the risk of secondary cancers in cancer survivors.
    • Findings may inform clinical strategies to mitigate second cancer risks associated with pediatric cancer treatments.